Suppr超能文献

交联对全血中溶解的纤维蛋白降解产物结构的影响。

Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.

作者信息

Carroll R C, Lockhart M S, Taylor F B

出版信息

J Lab Clin Med. 1984 May;103(5):695-703.

PMID:6232329
Abstract

The purpose of these studies was to establish the validity of 125I fibrin autoradiography--SDS gel techniques for monitoring degradation products from whole plasma or blood clots. These methods can be used to study fibrin degradation not only in patients with congenital factor XIII deficiency, but also in patients with disseminated intravascular coagulation or deep vein thrombosis during the course of thrombolytic therapy. Such an assay might complement existing immunologic techniques to characterize fibrin degradation in vivo by providing an in vitro analysis of the rate and pattern of fibrin degradation in whole blood or plasma. Fibrin degradation was traced by Coomassie blue staining for protein and by autoradiography on SDS-PAGE of degradation products released from a 125I-labeled fibrin tracer. The degradation of non-crosslinked clots from purified fibrin supplemented with plasmin showed a typical release of X, Y, D, and E fibrin fragments. Subsequently, all X and Y fragments were digested to D and E fragments. The degradation of non-crosslinked washed clots prepared from plasma supplemented with plasmin reflected the same pattern. The degradation of non-crosslinked washed clots prepared from EDTA anticoagulated plasma without added plasmin also showed release of X, Y, D, and E fragments. However, in contrast to the non-crosslinked washed clots supplemented with plasmin, there was no additional degradation of the X and Y fragments. These studies established that the pattern of degradation of the 125I-radiolabeled fibrin tracer was similar to that of the total protein released from the fibrin clot as observed by protein staining.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

这些研究的目的是确定125I纤维蛋白放射自显影-SDS凝胶技术监测全血浆或血凝块降解产物的有效性。这些方法不仅可用于研究先天性因子XIII缺乏症患者的纤维蛋白降解,还可用于研究溶栓治疗过程中弥散性血管内凝血或深静脉血栓形成患者的纤维蛋白降解。这样一种检测方法可能通过对全血或血浆中纤维蛋白降解的速率和模式进行体外分析,来补充现有的免疫技术以在体内表征纤维蛋白降解。通过考马斯亮蓝蛋白染色以及对从125I标记的纤维蛋白示踪剂释放的降解产物进行SDS-PAGE放射自显影来追踪纤维蛋白降解。补充纤溶酶的纯化纤维蛋白的非交联凝块的降解显示出典型的X、Y、D和E纤维蛋白片段的释放。随后,所有X和Y片段都被消化成D和E片段。补充纤溶酶的血浆制备的非交联洗涤凝块的降解反映了相同的模式。未添加纤溶酶的EDTA抗凝血浆制备的非交联洗涤凝块的降解也显示出X、Y、D和E片段的释放。然而,与补充纤溶酶的非交联洗涤凝块相比,X和Y片段没有进一步降解。这些研究表明,125I放射性标记的纤维蛋白示踪剂的降解模式与通过蛋白质染色观察到的纤维蛋白凝块释放的总蛋白的降解模式相似。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验